OSL OncoSil Medical Limited
Healthcare · Medical Devices
· website
$0.79
52wk 0.37 – 1.81
Overall
60.7
Value
79.4
Growth
100.0
Health
56.0
Quality
0.0
Momentum
50.2
Dividend
—
Price
About OncoSil Medical Limited
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company's lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
Price analytics
Returns
| 1 day | -3.7% |
| 1 week | -7.1% |
| 1 month | -25.1% |
| 3 months | -24.8% |
| 6 months | 56.4% |
| 1 year | -53.7% |
| 3 years | -76.8% |
Risk
| Volatility (1y ann.) | 100.1% |
| Beta vs ASX 200 | 0.25 |
| Sharpe (1y) | -0.34 |
| VaR 95% (1-day) | -7.9% |
| Max drawdown (1y) | -77.5% |
| Off 1-year high | -54.3% |
Technicals
| RSI(14) | 30 |
| vs 50DMA | -26.7% |
| vs 200DMA | -0.8% |
| Trend | Golden cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
79.4
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
43
Price / Sales
47
Growth
100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
100
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
56.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
57
Debt / Equity
100
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
50.2
6-month return vs ASX 200
100
Price vs 200-day average
47
Price vs 50-day average
0
Position in 52-week range
29
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$29.00M
P/E (trailing)
—
P/E (forward)
-0.04
EPS (trailing)
-0.48
Dividend yield
—
Payout ratio
0.0%
Beta
1.23
EV / EBITDA
-1.63
Price / Book
4.88
ROE
-268.2%
Operating margin
-336.6%
Net margin
-213.4%
Total cash
$6.48M
Total debt
$14,782
Current ratio
1.77
Debt / Equity
0.00
Free cash flow
$-6.30M
Avg volume
207,075
Latest annual results
(FY ending 30 Jun 2026)
- Revenue$1.68M
- Gross profit-$672.34K
- Operating income-$14.48M
- Net income-$10.86M
- Diluted EPS—
- Free cash flow-$10.47M
- Net debt-$6.46M